Breaking News Headlines Today | Ground News

New Year’s Sale — Build a balanced news diet with 40% off Vantage

Eyewire+ image

News from Eyewire+

Eyewire+’s media bias is unknown. Ground News is unable to assign a bias rating and does not have ratings available from Ad Fontes Media, AllSides, and Media Bias/Fact Check.

Eyewire+’s aggregated factuality score is Unknown. Factuality is assigned by combining fact check, credibility, and reliability ratings from Ad Fontes Media and Media Bias/Fact Check.

Information about Eyewire+

Where is Eyewire+ located?Eyewire+'s Website

Media Bias Ratings

Do you disagree?

Edit bias

Learn more about Media Bias Ratings.

Factuality

Learn more about Factuality Ratings

Reveal Factuality Ratings by upgrading to a Premium account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Ownership

Learn more about Ownership categories

Reveal Ownership Data by upgrading to a Vantage account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Top Eyewire+ News

Ollin Biosciences Reports Positive Head-to-Head Phase 1b Results for OLN324 in DME and Wet AMD

Suzhou, China · Suzhou

Ollin Biosciences Reports Positive Head-to-Head Phase 1b Results for OLN324 in DME and Wet AMD

100% Center coverage: 10 sources

Ollin Biosciences announced positive topline results from its randomized, head-to-head phase 1b JADE clinical study evaluating OLN324, a next-generation VEGF/Ang2 bispecific antibody, versus faricimab (Vabysmo; Genentech). The study enrolled more than 160 patients with diabetic macular edema (DME) or wet age-related macular degeneration (AMD) across sites in the United States. According to Ollin, the results demonstrated that OLN324 achieved fas…See the Story

Annexon Submits European Marketing Application for First Targeted Treatment for Guillain-Barré Syndrome

California, United States · California

Annexon Submits European Marketing Application for First Targeted Treatment for Guillain-Barré Syndrome

100% Center coverage: 1 sources

Annexon has submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for tanruprubart for the treatment of Guillain-Barré syndrome (GBS). Annexon is the developer of vonaprument, which is in phase 3 development for the treatment of dry age-related macular degeneration (AMD) with geographic atrophy (GA). Vonaprument is a first-in-kind, non-pegylated antigen-binding fragment (Fab) designed to block C1q locally i…See the Story

Complement Therapeutics Announces FDA Fast Track Designation for CTx001 for the Treatment of Geographic Atrophy Secondary to AMD - PressReach

Complement Therapeutics Announces FDA Fast Track Designation for CTx001 for the Treatment of Geographic Atrophy Secondary to AMD - PressReach

FDA Fast Track designation has been granted to CTx001 for Geographic Atrophy secondary to Age-related Macular Degeneration CTx001 is an investigational AAV-based gene therapy designed to modulate multiple pathways of the complement system CTx001 has previously received FDA IND clearance and will be evaluated in Opti-GAIN, a first-in-human Phase I/II clinical trial MUNICH, Jan. 8, 2026 /PRNewswire/ — Complement Therapeutics GmbH (CTx), a clinical…See the Story

Breaking News Topics Related to Eyewire+